| Literature DB >> 30808235 |
Mickaël Guilbaud1, Marie Devaux1, Celia Couzinié1, Johanne Le Duff1, Alice Toromanoff1, Céline Vandamme1, Nicolas Jaulin1, Gwladys Gernoux1, Thibaut Larcher2, Philippe Moullier1, Caroline Le Guiner1, Oumeya Adjali1.
Abstract
Anti-transgene immune responses elicited after intramuscular (i.m.) delivery of recombinant adeno-associated virus (rAAV) have been shown to hamper long-term transgene expression in large-animal models of rAAV-mediated gene transfer. To overcome this hurdle, an alternative mode of delivery of rAAV vectors in nonhuman primate muscles has been described: the locoregional (LR) intravenous route of administration. Using this injection mode, persistent inducible transgene expression for at least 1 year under the control of the tetracycline-inducible Tet-On system was previously reported in cynomolgus monkeys, with no immunity against the rtTA transgene product. The present study shows the long-term follow-up of these animals. It is reported that LR delivery of a rAAV2/1 vector allows long-term inducible expression up to at least 5 years post gene transfer, with no any detectable host immune response against the transactivator rtTA, despite its immunogenicity following i.m. gene transfer. This study shows for the first time a long-term regulation of muscle gene expression using a Tet-On-inducible system in a large-animal model. Moreover, these findings further confirm that the rAAV LR delivery route is efficient and immunologically safe, allowing long-term skeletal muscle gene transfer.Entities:
Keywords: AAV; gene transfer; immunogenicity; locoregional delivery; long-term follow-up; nonhuman primate
Year: 2019 PMID: 30808235 PMCID: PMC6648187 DOI: 10.1089/hum.2018.234
Source DB: PubMed Journal: Hum Gene Ther ISSN: 1043-0342 Impact factor: 5.695